Anabolic effects of nandrolone decanoate in patients receiving dialysis - A randomized controlled trial

被引:171
作者
Johansen, KL
Mulligan, K
Schambelan, M
机构
[1] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div Nephrol, San Francisco, CA USA
[2] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div Endocrinol, San Francisco, CA USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1999年 / 281卷 / 14期
关键词
D O I
10.1001/jama.281.14.1275
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Patients receiving dialysis commonly experience malnutrition, reduced muscle mass (sarcopenia), and fatigue for which no effective treatment has been identified. Anabolic steroids are known to increase muscle mass and strength in healthy individuals, but their effect on the sarcopenia and fatigue associated with long-term dialysis has not been evaluated. Objective To assess the effects of an anabolic steroid, nandrolone decanoate, on lean body mass (LBM), functional status, and quality of life in dialysis patients. Design Randomized, double-blind, placebo-controlled trial conducted between April 1996 and July 1997. Setting Hospital-based outpatient dialysis unit. Patients Twenty-nine patients undergoing dialysis for at least 3 months. Intervention Nandrolone decanoate, 100 mg (n = 14), or placebo (n = 15) by intramuscular injection once a week for 6 months. Main Outcome Measures Weight, LBM, fatigue, grip strength, walking and stair-climbing times, and treadmill performance after 3 and 6 months of treatment. Results Lean body mass increased significantly in patients given nandrolone compared with patients given placebo (mean change [SD], +4.5 [2.3] kg; P<.001 compared with baseline). This effect was significantly greater than the change in LBM in the placebo group (mean change [SD], +1.9 [1.6] kg; P = .003 compared with baseline; P = .005 compared with nandrolone group). Serum creatinine levels increased in the nandrolone group (+168 [203] mmol/L [1.9 {2.3} mg/dL]; P = .02) but not in the placebo group (-4.0 [177] mmol/L [0.04 {2.0} mg/dL]; P = .95), suggesting an increase in muscle mass. Time to complete the walking and stair-climbing test decreased from 36.5 to 32.7 seconds in the nandrolone group, while those in the placebo group increased from 38.7 to 42.1 seconds (P = .05). Peak oxygen consumption increased in the individuals in the nandrolone group who performed treadmill tests, but not to a statistically significant degree. Grip strength did not change in either group. Conclusions Treatment with nandrolone for 6 months resulted in a significant increase in LBM associated with functional improvement in patients undergoing dialysis.
引用
收藏
页码:1275 / 1281
页数:7
相关论文
共 40 条
[1]  
*AM COLL SPORTS ME, 1991, GUID EX TEST PRESCR
[2]  
Avram MM, 1996, ADV PERIT D, V12, P266
[3]  
Bartens W, 1996, PERITON DIALYSIS INT, V16, P27
[4]   THE SICKNESS IMPACT PROFILE - DEVELOPMENT AND FINAL REVISION OF A HEALTH-STATUS MEASURE [J].
BERGNER, M ;
BOBBITT, RA ;
CARTER, WB ;
GILSON, BS .
MEDICAL CARE, 1981, 19 (08) :787-805
[5]   The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men [J].
Bhasin, S ;
Storer, TW ;
Berman, N ;
Callegari, C ;
Clevenger, B ;
Phillips, J ;
Bunnell, TJ ;
Tricker, R ;
Shirazi, A ;
Casaburi, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (01) :1-7
[6]   SYMPTOMATIC NON-INSULIN-DEPENDENT DIABETES-MELLITUS DURING THERAPY WITH RECOMBINANT HUMAN GROWTH-HORMONE [J].
BOTERO, D ;
DANON, M ;
BROWN, RS .
JOURNAL OF PEDIATRICS, 1993, 123 (04) :590-592
[7]   IMPAIRED NUTRITIVE SKELETAL-MUSCLE BLOOD-FLOW IN PATIENTS WITH CHRONIC-RENAL-FAILURE [J].
BRADLEY, JR ;
ANDERSON, JR ;
EVANS, DB ;
COWLEY, AJ .
CLINICAL SCIENCE, 1990, 79 (03) :239-245
[8]  
CAMPBELL A, 1976, QUALITY AM LIFE
[9]  
CHURCHILL DN, 1987, CLIN INVEST MED, V10, P14
[10]  
COLES GA, 1972, Q J MED, V41, P25